NCT00217438View on ClinicalTrials.gov

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2012

Conditions
Refractory Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
Interventions
DRUG

melphalan

Given IV

DRUG

amifostine trihydrate

Given IV

PROCEDURE

peripheral blood stem cell transplantation

Undergo PBSCT

GENETIC

fluorescence in situ hybridization

Correlative study

PROCEDURE

bone marrow ablation with stem cell support

Undergo transplant

Trial Locations (4)

14642

University of Rochester, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00217438 - Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | Biotech Hunter | Biotech Hunter